Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 28, 10, (2183-2193), 10.1038/s41591-022-01919-8)

Abstract

In the version of this article initially published, in the first and final paragraphs of the Results section, the dosing schedule for pepinemab administration was described in error as “four times per week” instead of “every four weeks,” while in the Fig. 4b color key, the bottom, dark green key now reading “Much improved” appeared originally as “Minimally improved.” The errors have been corrected in the HTML and PDF versions of the article.